Oncology

Ron Barkley, president of the Cancer Center Business Development Group, which consults with oncology providers on value-based care arrangements, shares tips.

CEO of a Pennsylvania-based oncology group shares how participating in a new value-based model is changing the care approach.

Healthcare systems stand to lose $6 million if burned out physicians choose to resign or work elsewhere. Here are some ways to curb burnout and its associated costs.

Genetic testing is playing a growing role in diagnosing and treating diseases, particularly when it comes to certain cancers and rheumatic conditions.

Successful CAR T-cell therapy reimbursement begins with careful payer-provider collaboration and taking these two approaches.

Shift represents growing understanding of value of genetic testing for cancers. Find out who is receiving the test and why.

Two new studies reveal that cost-restraints can keep patients from accessing life-preserving cancer drugs.

The impact of VBRs on outcomes, VBRs versus other healthcare reimbursement initiatives, and VBR successes and failures. Pfizer’s Robert Popovian, PharmD, weighs in.

FDA expanded the indication on cabozantinib (Cabometyx, Exelixis) to treat patients with advanced renal cell carcinoma (RCC).

Early detection of breast cancer continues to be the best way to save lives and decrease healthcare costs over time, and new technology could help.

Experts say a cancer care revolution is here. Here’s a closer look at some advancements in cancer treatments to watch.

Key takeaways for healthcare executives from Bruno Medeiros, MD, associate professor of medicine (hematology) at the Stanford University Medical Center and director of Cancer Center Infusion Area Treatment Services at Stanford Cancer Center.

Acute myeloid leukemia experts share promising new developments on the oncology horizon.

Physicians need to be able to move quickly to care for patients with AML, and they need to have payers on board.

There are several possible reasons that breastfeeding may influence breast cancer risk, according to the American Institute of Cancer Research. Find out what they are.

New research shows that these certain patients with breast cancer can benefit from genetic testing for all breast cancer genes.

The medication’s ability to reduce inflammation sited as one possible explanation.

Study highlights the need for services and research for this understudied population.

Study shows Clovis Oncology’s rucaparib shows clinically meaningful impact in delaying disease recurrence in ovarian cancer.

Understanding genetic variations and tumor differences in black women with breast cancer could lead to personalized diagnosis and treatment.

New research shows hypertension, diabetes influence survival of ovarian cancer patients in different ways.

Alcohol consumption is known to be a risk factor for breast cancer based on studies predominantly done in white women. Now, a University of North Carolina Lineberger Comprehensive Cancer Center study has found the same risk exists for black women.

A new study provides new insights into the epidemiology of breast cancer among the most prominent Asian-American ethnic groups in California.

New findings reveal this genetic test to assess breast cancer risk could be more effective than others.

Oncology is a complex and rapidly-evolving management challenge for payers.

Biomarker testing for harmful genetic mutations provides the opportunity to identify at-risk individuals who might benefit from risk modification strategies and/or enhanced disease screening.

Inherited susceptibilities to leukemias are becoming better understood and have important implications for screening, prevention, genetic counseling, and treatment.

Investigational gene therapies might reduce the suffering and death caused by this genetic disease.

As development of molecular biomarkers hastens, administrators, clinicians and regulators are working to organize and define biomarkers’ appropriate roles in clinical care-and discussing how to efficiently share the massive amounts of genomic data that will result.